Find and Pitch Jounalists, Get Your Story Covered

Tags: BioPharma, Legal, Pharma

	Profile	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site - 11 days ago Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs - about 2 months ago Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings - about 2 months ago FDA Says ‘No’ to Novo Nordisk’s Once-Weekly Insulin - 6 months ago Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease - 6 months ago Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds - 8 months ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent - 21 days ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 6 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 6 months ago STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 7 months ago STAT+: Pharmalittle: We’re reading about a GLP-1 side effect, U.K. clinical trial transparency, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Ozempic tackling kidney disease, OTC birth control, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 11 months ago STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade - about 1 year ago STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data - about 1 year ago STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment - about 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - about 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit - about 1 year ago STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy - about 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - about 1 year ago STAT+: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny - over 1 year ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Pharma giants vie for oral GLP-1R approval - 25 days ago
4	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Novo Nordisk sells hit weight-loss drug in China—at fraction of US price - about 1 month ago
5	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	A diabetes drug, twice rejected, stumbles again — but its developer persists - about 2 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Novo Nordisk reports continued growth in obesity drug sales - about 2 months ago STAT+: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion - 9 months ago STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows - 10 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 12 months ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Novo Nordisk reports continued growth in obesity drug sales - about 2 months ago STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - about 2 months ago STAT+: Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study - 2 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 5 months ago STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease - 7 months ago STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk - 10 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 12 months ago STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation - about 1 year ago Wegovy cuts risk of heart attacks in milestone cardiovascular trial - about 1 year ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - about 1 year ago Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award - about 1 year ago STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies - about 1 year ago
8	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs - 12 months ago
9	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money - 4 months ago If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy - 6 months ago Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy? - 9 months ago Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now. - 10 months ago Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy? - about 1 year ago Yet Again, Ozempic Could Soon Get Even Better for Novo Nordisk Stock - over 1 year ago
10	Adam Spatacco Motley Fool Community for top investors. Investingcommunity	Did Eli Lilly Just Get a Leg Up on Novo Nordisk? - 6 months ago With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk? - 9 months ago Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic - 10 months ago Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why - 10 months ago Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year. - 10 months ago Novo Nordisk's Magic Run Continues Even With Increasing Competition - 11 months ago Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited - 11 months ago

Journalists covering Novo Nordisk